- Title
- Australian National Clinical Evidence Taskforce COVID-19 drug treatment guidelines: challenges of producing a living guideline
- Creator
- Barber, Bridget E.; White, Heath; Poole, Alexis P.; Davis, Joshua S.; McGloughlin, Steven A.; Turner, Tari
- Relation
- Medical Journal of Australia Vol. 219, Issue 5, p. 197-199
- Publisher Link
- http://dx.doi.org/10.5694/mja2.52044
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2023
- Description
- The National Clinical Evidence Taskforce (NCET) established coronavirus disease 2019 (COVID-19) drug treatment guidelines in March 2020 to provide clinicians with living evidence-based recommendations for the care of patients with COVID-19. These guidelines have been widely used and have informed practice in Australia and beyond. However, there are limitations to the available evidence, and, as the COVID-19 pandemic has progressed, the NCET has had to address a number of challenges. This perspective article discusses these limitations and challenges and the strategies developed to ensure that the guidelines remain relevant and useful for clinicians (Box).
- Subject
- COVID-19; guidelines as topic; National Clinical Evidence Taskforce (NCET); drug treatment; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1487876
- Identifier
- uon:52283
- Identifier
- ISSN:0025-729X
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 1142
- Visitors: 1122
- Downloads: 0
Thumbnail | File | Description | Size | Format |
---|